ClinicalTrials.gg
CompletedNCT03395470Updated Aug 24, 2018

Safety, Tolerability and PK of PXL770 in Healthy Male Subjects

A Phase 1 interventional study of PXL770 and Placebo in Metabolic Disease, sponsored by Poxel SA. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-24.

Sponsored by Poxel SA · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

PXL770 is a direct activator of 5' adenosine monophosphate-activated protein kinase (AMPK) being developed by Poxel S.A. for the treatment of type 2 diabetes mellitus (T2DM). In Part A of this study, we'll test the safety, tolerability and pharmacokinetics (PK) of repeated doses. In Part B, we'll co-administer PXL770 and rosuvastatin (a HMG-CoA reductase inhibitor) to assess any drug-drug interaction.

02

Conditions studied

  • Metabolic Disease

Browse trials for

03

In context

Metabolic Diseases

763 studies on the registry are indexed under Metabolic Diseases; 192 are open to participants now.

This study's enrollment of 60 is above the median of 50 across 525 interventional studies indexed under Metabolic Diseases.

Browse Metabolic Diseases studies →

Lead sponsor

Poxel SA is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male subjects deemed healthy on the basis of a clinical history, physical examination, , vital signs, and laboratory tests of blood and urine
  • in the range 18.5-29.9 kg/m²
  • body weight at least 60 kg
  • willing to use reliable
  • able to give fully informed written consent.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating woman, or sexually active woman of not using reliable
  • abnormal findings at the screening assessment
  • Clinically significant vital signs outside the acceptable range at screening
  • Clinically relevant abnormal medical history, surgery or concurrent medical condition
  • Acute or chronic illness
  • Estimated less than 80 mL/min/1.73 m2
  • Severe adverse reaction to any drug or sensitivity to the trial medication or its components
  • Significant food allergy; vegetarian or vegan
  • Participation in other clinical trials of unlicensed or prescription medicines, or loss of more than 400 mL blood, within the 3 months before first dose of trial medication
  • Drug or alcohol abuse
  • Smoking of more than 5 cigarettes daily
  • Possibility that subject will not cooperate
  • Positive test for \& C,
  • Objection by a General Practitioner
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Group A1

    Dose 1 or placebo

    Drug: PXL770 · Drug: Placebo

  • Experimental
    Group A2

    Dose 2 or placebo

    Drug: PXL770 · Drug: Placebo

  • Experimental
    Group A3

    Dose 3 or placebo

    Drug: PXL770 · Drug: Placebo

  • Experimental
    Group A4

    Dose 4 or placebo

    Drug: PXL770 · Drug: Placebo

  • Experimental
    Group A5

    Dose 5 or placebo

    Drug: PXL770 · Drug: Placebo

  • Experimental
    Group B

    Dose + Rosuvastatin

    Drug: PXL770 · Drug: Rosuvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: PK parameters of PXL770 after repeated doses Part B: PK parameters of rosuvastatin before and after repeated doses of PXl770

    - Cmax: peak plasma concentration after dosing

    Time frame: From baseline to day 14

  2. Part A: PK parameters of PXL770 after repeated doses

    - AUC0-t: area under the concentration-time curve from 0 extrapolated to time t

    Time frame: From baseline to day 14

  3. Part A: PK parameters of PXL770 after repeated doses

    - AUC0-∞: area under the concentration-time curve from 0 extrapolated to infinite

    Time frame: From baseline to day 14

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Incidence of treatment emergent adverse events

    Time frame: From baseline to day 14

07

Study locations

1 site
  • Hammersmith Medicines Research (HMR)
    London, United Kingdom
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03395470
Lead sponsor
Poxel SA
Responsible party
Sponsor
First posted
Jan 10, 2018
Start date
Aug 21, 2017
Primary completion
Mar 16, 2018
Completion
Mar 16, 2018
Last update
Aug 24, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pxl-770

Start the discussion